Skip to main content
. 2023 Apr 3;128(11):2072–2080. doi: 10.1038/s41416-023-02248-4

Fig. 2. Overall survival and first-line progression-free survival according to gBRCA groups at treatment initiation and type of first-line treatment.

Fig. 2

gBRCAwt, gBRCAm and untested patients are pictures in green, red and blue respectively.